<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:07:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8483230" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8483230</identifier>
        <datestamp>2021-10-01</datestamp>
        <setSpec>ajrccm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="publisher-id">ajrccm</journal-id>
              <journal-title-group>
                <journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1073-449X</issn>
              <issn pub-type="epub">1535-4970</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8483230</article-id>
              <article-id pub-id-type="pmcid">PMC8483230</article-id>
              <article-id pub-id-type="pmc-uid">8483230</article-id>
              <article-id pub-id-type="pmid">33734030</article-id>
              <article-id pub-id-type="pmid">33734030</article-id>
              <article-id pub-id-type="publisher-manuscript">202102-0509OC</article-id>
              <article-id pub-id-type="doi">10.1164/rccm.202102-0509OC</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                  <subj-group>
                    <subject>Cystic Fibrosis</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <italic>F508del</italic> Allele</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zemanick</surname>
                    <given-names>Edith T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fna1">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor-Cousar</surname>
                    <given-names>Jennifer L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fna1">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davies</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gibson</surname>
                    <given-names>Ronald L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4057-2199</contrib-id>
                  <name>
                    <surname>Mall</surname>
                    <given-names>Marcus A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McKone</surname>
                    <given-names>Edward F.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7102-1712</contrib-id>
                  <name>
                    <surname>McNally</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramsey</surname>
                    <given-names>Bonnie W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fna2">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rayment</surname>
                    <given-names>Jonathan H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9045-0133</contrib-id>
                  <name>
                    <surname>Rowe</surname>
                    <given-names>Steven M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tullis</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahluwalia</surname>
                    <given-names>Neil</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chu</surname>
                    <given-names>Chenghao</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ho</surname>
                    <given-names>Thang</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moskowitz</surname>
                    <given-names>Samuel M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noel</surname>
                    <given-names>Sabrina</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tian</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Waltz</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weinstock</surname>
                    <given-names>Tanya G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Xuan</surname>
                    <given-names>Fengjuan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wainwright</surname>
                    <given-names>Claire E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fna3">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McColley</surname>
                    <given-names>Susanna A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff17">
                    <sup>17</sup>
                  </xref>
                  <xref ref-type="corresp" rid="fna3">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="collab">
                  <collab>
                    <on-behalf-of>for the VX18-445-106 Study Group</on-behalf-of>
                  </collab>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, Colorado;</aff>
                <aff id="aff2"><label><sup>2</sup></label>Department of Medicine and</aff>
                <aff id="aff3"><label><sup>3</sup></label>Department of Pediatrics, National Jewish Health, Denver, Colorado;</aff>
                <aff id="aff4"><label><sup>4</sup></label>National Heart and Lung Institute, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre and Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom;</aff>
                <aff id="aff5"><label><sup>5</sup></label>University of Washington/Seattle Children’s Hospital, Seattle, Washington;</aff>
                <aff id="aff6"><label><sup>6</sup></label>Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany;</aff>
                <aff id="aff7"><label><sup>7</sup></label>Berlin Institute of Health, Berlin, Germany;</aff>
                <aff id="aff8"><label><sup>8</sup></label>German Center for Lung Research, Berlin, Germany;</aff>
                <aff id="aff9"><label><sup>9</sup></label>St. Vincent’s University Hospital and University College, Dublin, Ireland;</aff>
                <aff id="aff10"><label><sup>10</sup></label>Children’s Health Ireland and Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland;</aff>
                <aff id="aff11"><label><sup>11</sup></label>British Columbia Children’s Hospital, Vancouver, British Columbia, Canada;</aff>
                <aff id="aff12"><label><sup>12</sup></label>University of Alabama at Birmingham, Birmingham, Alabama;</aff>
                <aff id="aff13"><label><sup>13</sup></label>St. Michael’s Hospital, Toronto, Ontario, Canada;</aff>
                <aff id="aff14"><label><sup>14</sup></label>Vertex Pharmaceuticals Incorporated, Boston, Massachusetts;</aff>
                <aff id="aff15"><label><sup>15</sup></label>University of Queensland, Brisbane, Queensland, Australia;</aff>
                <aff id="aff16"><label><sup>16</sup></label>Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois; and</aff>
                <aff id="aff17"><label><sup>17</sup></label>Northwestern University Feinberg School of Medicine, Chicago, Illinois</aff>
              </contrib-group>
              <contrib-group>
                <on-behalf-of>for the VX18-445-106 Study Group</on-behalf-of>
              </contrib-group>
              <author-notes>
                <corresp>Correspondence and requests for reprints should be addressed to Susanna A. McColley, M.D., Ann and Robert H. Lurie Children’s Hospital of Chicago, 303 E Superior Street #205, Chicago, IL 60611. E-mail: <email xlink:href="mailto:smccolley@luriechildrens.org">smccolley@luriechildrens.org</email>.</corresp>
                <fn id="fna1">
                  <label>*</label>
                  <p>These authors contributed equally to this work.</p>
                </fn>
                <fn id="fna2">
                  <label>
                    <sup>‡</sup>
                  </label>
                  <p>B.W.R. is Associate Editor of <italic>AJRCCM</italic>. Her participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.</p>
                </fn>
                <fn id="fna3">
                  <label>
                    <sup>§</sup>
                  </label>
                  <p>These authors contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date date-type="pub" publication-format="electronic">
                <day>15</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date date-type="collection" publication-format="electronic">
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>15</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>203</volume>
              <issue>12</issue>
              <fpage>1522</fpage>
              <lpage>1532</lpage>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2021 by the American Thoracic Society</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>). For commercial usage and reprints, please contact Diane Gern (<email xlink:href="mailto:dgern@thoracic.org">dgern@thoracic.org</email>).</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="rccm.202102-0509OC.pdf"/>
              <abstract>
                <p><bold>Rationale:</bold> Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one <italic>F508del-CFTR</italic> (cystic fibrosis transmembrane conductance regulator) allele, but it has not been evaluated in children &lt;12 years of age.</p>
                <p><bold>Objectives:</bold> To assess the safety, pharmacokinetics, and efficacy of ELX/TEZ/IVA in children 6 through 11 years of age with <italic>F508del</italic>–minimal function or <italic>F508del</italic>-<italic>F508del</italic> genotypes.</p>
                <p><bold>Methods:</bold> In this 24-week open-label phase 3 study, children (<italic>N</italic> = 66) weighing &lt;30 kg received 50% of the ELX/TEZ/IVA adult daily dose (ELX 100 mg once daily, TEZ 50 mg once daily, and IVA 75 mg every 12 h) whereas children weighing ⩾30 kg received the full adult daily dose (ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 h).</p>
                <p><bold>Measurements and Main Results:</bold> The primary endpoint was safety and tolerability. The safety and pharmacokinetic profiles of ELX/TEZ/IVA were generally consistent with those observed in older patients. The most commonly reported adverse events included cough, headache, and pyrexia; in most of the children who had adverse events, these were mild or moderate in severity. Through Week 24, ELX/TEZ/IVA treatment improved the percentage of predicted FEV<sub>1</sub> (10.2 percentage points; 95% confidence interval [CI], 7.9 to 12.6), Cystic Fibrosis Questionnaire–Revised respiratory domain score (7.0 points; 95% CI, 4.7 to 9.2), lung clearance index<sub>2.5</sub> (−1.71 units; 95% CI, −2.11 to −1.30), and sweat chloride (−60.9 mmol/L; 95% CI, −63.7 to −58.2); body mass index-for-age <italic>z</italic>-score increased over the 24-week treatment period when compared with the pretreatment baseline.</p>
                <p><bold>Conclusions:</bold> Our results show ELX/TEZ/IVA is safe and efficacious in children 6 through 11 years of age with at least one <italic>F508del-CFTR</italic> allele, supporting its use in this patient population.</p>
                <p>Clinical trial registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT03691779).</p>
              </abstract>
              <kwd-group>
                <title>Keywords</title>
                <kwd>cystic fibrosis</kwd>
                <kwd>elexacaftor</kwd>
                <kwd>tezacaftor</kwd>
                <kwd>ivacaftor</kwd>
                <kwd>child</kwd>
              </kwd-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="3"/>
                <ref-count count="30"/>
                <page-count count="45"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float" orientation="portrait">
              <sec>
                <title>At a Glance Commentary</title>
                <sec>
                  <title>Scientific Knowledge on the Subject</title>
                  <p>Previous studies showed that the CFTR (cystic fibrosis transmembrane conductance regulator) modulator elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is safe and efficacious in patients ⩾12 years of age with cystic fibrosis and at least one <italic>F508del-CFTR</italic> allele. Clinical benefits with ELX/TEZ/IVA exceeded those seen with previous CFTR modulators indicated for this patient population. As the clinical consequences of cystic fibrosis often begin to manifest in early childhood, it is crucial to initiate treatment as early as possible.</p>
                </sec>
                <sec>
                  <title>What This Study Adds to the Field</title>
                  <p>To evaluate the safety and efficacy of ELX/TEZ/IVA treatment in younger patients, we conducted a 24-week phase 3 open-label study in children 6 through 11 years of age with cystic fibrosis and at least one <italic>F508del-CFTR</italic> allele. Our results demonstrate that the safety and efficacy of ELX/TEZ/IVA in these children are consistent with those reported in adults and adolescents with cystic fibrosis, supporting use of ELX/TEZ/IVA in this younger patient population.</p>
                </sec>
              </sec>
            </boxed-text>
            <p content-type="flushleft">Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the <italic>CFTR</italic> (CF transmembrane conductance regulator) gene (<xref rid="B1" ref-type="bibr">1</xref>). In some regions of the world, nearly 90% of patients with CF have at least one <italic>F508del-CFTR</italic> mutation, resulting in decreased quantity and function of the CFTR protein at epithelial surfaces, including in the respiratory tract, pancreas, gastrointestinal system, and sweat glands (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). The clinical consequences of impaired CFTR function generally appear in the first year of life, with pancreatic insufficiency, impaired growth, and progressive lung disease appearing as early childhood manifestations of CF (<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B7" ref-type="bibr">7</xref>). Prompt diagnosis in combination with effective treatment starting early in life improves clinical outcomes and life expectancy in patients with this multisystem disease (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>).</p>
            <p>CFTR modulators are small-molecule therapeutics that treat the underlying cause of CF; correctors improve CFTR protein processing and trafficking, while potentiators enhance channel gating (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Recently, the efficacy and safety of a triple combination regimen composed of the CFTR correctors elexacaftor and tezacaftor and the CFTR potentiator ivacaftor (ELX/TEZ/IVA) was established in patients with CF ≥12 years of age with at least one <italic>F508del-CFTR</italic> allele (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). In pivotal studies, treatment with ELX/TEZ/IVA led to robust improvements in lung function, respiratory symptoms, and CFTR function in patients with <italic>F508del</italic>-minimal function (<italic>F</italic>/MF) genotypes (<xref rid="B13" ref-type="bibr">13</xref>). As minimal function mutations result in either a complete absence of CFTR protein or a protein that cannot be modulated by TEZ and IVA, the responsiveness to ELX/TEZ/IVA in these patients is attributable to the single <italic>F508del</italic> allele (<xref rid="B13" ref-type="bibr">13</xref>). ELX/TEZ/IVA treatment was also found to be highly effective and provided substantially greater efficacy compared with the dual combination of TEZ/IVA in patients homozygous for <italic>F508del-CFTR</italic> (<italic>F</italic>/<italic>F</italic>) (<xref rid="B12" ref-type="bibr">12</xref>). These results demonstrate the ability of ELX/TEZ/IVA to address the disease-causing defect present in a large majority of patients with CF ⩾ 12 years of age.</p>
            <p>The safety and efficacy of CFTR modulators have also been studied in children with CF. In children &lt;12 years of age, the safety of CFTR modulators is consistent with the safety in patients ≥12 years of age (<xref rid="B14" ref-type="bibr">14</xref>–<xref rid="B16" ref-type="bibr">16</xref>). IVA treatment improved percentage of predicted FEV<sub>1</sub> (ppFEV<sub>1</sub>) and decreased sweat chloride concentrations in children 6 through 11 years of age with <italic>CFTR</italic> gating mutations (<xref rid="B14" ref-type="bibr">14</xref>). In children 6 through 11 years of age homozygous for <italic>F508del</italic>, treatment with either TEZ/IVA or the dual combination modulator lumacaftor/IVA improved sweat chloride concentration and Cystic Fibrosis Questionnaire–Revised (CFQ-R) respiratory domain score (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Although these studies collectively indicate that early intervention with CFTR modulators in children &lt;12 years of age can provide substantial clinical benefit, a critical need remains for more effective CFTR modulation in children &lt;12 years of age who have at least one <italic>F508del</italic> allele.</p>
            <p>Given the robust clinical improvements observed with ELX/TEZ/IVA treatment in patients ⩾12 years of age, as well as the unmet need in younger patients with at least one <italic>F508del</italic> allele, we evaluated the safety, pharmacokinetics (PK), and efficacy of ELX/TEZ/IVA in children 6 through 11 years of age with <italic>F</italic>/MF or <italic>F</italic>/<italic>F</italic> genotypes. As children in this age range who have the <italic>F/F</italic> genotype can be treated with approved dual-combination CFTR modulator regimens such as lumacaftor/IVA or TEZ/IVA, we used an open-label study design that prioritized safety data collection and within-group efficacy analysis rather than a blinded, randomized controlled trial design.</p>
            <sec sec-type="methods" id="s1">
              <title>Methods</title>
              <sec id="s1A">
                <title>Patients, Trial Design, and Oversight</title>
                <p content-type="flushleft">This phase 3, two-part, open-label, multicenter trial of ELX/TEZ/IVA enrolled children 6 through 11 years of age with CF and either <italic>F</italic>/MF or <italic>F/F</italic> genotypes. The <italic>CFTR</italic> genotype, part of the basis for the diagnosis of CF, was confirmed at screening. Qualifying minimal function mutations (<italic>see</italic> Table E1 in the online supplement) and other eligibility criteria are provided in the online supplement. All patients stopped or remained off CFTR modulators for ⩾28 days before the Day 1 visit.</p>
                <p>Part A of the study evaluated PK, safety, and tolerability of ELX/TEZ/IVA over a 2-week treatment period. Part B evaluated safety, tolerability, efficacy, and PK over a 24-week treatment period (Figure E1). Additional trial design details, including dosing and outcome measures for part A and eligibility criteria for both parts of the study, are provided in the online supplement.</p>
                <p>Dosing for part B was based on weight at baseline. Children weighing &lt;30 kg received 50% of the adult daily dose (ELX 100 mg once daily, TEZ 50 mg once daily, and IVA 75 mg every 12 h), whereas children weighing ⩾30 kg received the full adult daily dose (ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 h).</p>
                <p>The trial was designed by Vertex Pharmaceuticals in collaboration with the authors. For each enrolled child, informed consent was provided by a parent or legal guardian; assent was obtained from patients in accordance with local requirements. Safety was monitored by an independent data safety monitoring committee. Data collection and analysis were performed by Vertex Pharmaceuticals in collaboration with the authors and the VX18-445-106 Study Group. All authors had full access to the trial data after final database lock, critically reviewed the manuscript, and approved the manuscript for submission. The investigators vouch for the accuracy and completeness of the data generated at their respective sites, and the investigators and Vertex Pharmaceuticals vouch for the fidelity of the trial to the protocol. Confidentiality agreements were in place between the sponsor and each investigative site during the trial.</p>
                <p>As part B of the study overlapped with the early months of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a global protocol addendum that enabled in-home assessments was implemented. Patient access to study drug therapy and collection of safety data were prioritized. Implemented measures were enabled based on country and local regulations, as well as site-level considerations, and included, as applicable, remote consent, shipment of the study drug to the patient’s home, virtual study visits conducted by site personnel via teleconference, home nursing visits for blood draws, in-home assessments, and remote monitoring. Additional details can be found in the online supplement.</p>
                <p>The clinical trial protocol, SARS-CoV-2–related protocol addendum, and informed consent forms were approved by independent ethics committees for each region or site, as required by local regulations.</p>
              </sec>
              <sec id="s1B">
                <title>Outcome Measures</title>
                <p content-type="flushleft">The primary endpoint for part B was safety and tolerability. Secondary endpoints included absolute change from baseline through Week 24 in ppFEV<sub>1</sub>, sweat chloride concentration, and CFQ-R respiratory domain score; absolute change from baseline at Week 24 in body mass index (BMI), weight, height, and corresponding for-age <italic>z</italic>-scores; number of pulmonary exacerbations and CF-related hospitalizations through Week 24; PK parameters of ELX, TEZ, and IVA; and absolute change from baseline through Week 24 in lung clearance index<sub>2</sub><sub>.5</sub> (LCI<sub>2.5</sub>). The proportion of patients achieving sweat chloride concentrations &lt;60 mmol/L and &lt;30 mmol/L was assessed as a <italic>post hoc</italic> analysis. Additional details are provided in the online supplement.</p>
              </sec>
              <sec id="s1C">
                <title>Statistical Analysis</title>
                <p content-type="flushleft">Safety, efficacy, and PK analyses included children who received ⩾1 dose of ELX/TEZ/IVA. The main analyses were based on data collected up to Week 24; additional analyses were conducted to account for data collected at unscheduled visits beyond Week 24 as detailed in the online supplement. The main analyses for safety were based on all data collected up to Week 24, including both in-clinic and at-home assessments. The main analyses for all efficacy endpoints included only those data that had been collected in clinic through the Week 24 visit.</p>
                <p>Absolute change from baseline in ppFEV<sub>1</sub>, sweat chloride concentration, CFQ-R respiratory domain score, LCI<sub>2.5</sub>, and nutritional parameters were analyzed using a mixed-effects model for repeated measures. <italic>Post hoc</italic> analyses of genotype subgroups were performed in a similar manner to the main efficacy analysis. Details of the analysis, including management of missing data resulting from the SARS-CoV-2 pandemic, are provided in the online supplement.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s2">
              <title>Results</title>
              <sec id="s2A">
                <title>Population</title>
                <p content-type="flushleft">Part A enrollment details and baseline characteristics are provided in Table E2; there were 16 participants and all completed the 2-week treatment period. Part B of the trial was conducted at 21 sites in five countries from August 5, 2019, to August 7, 2020. Overall, 66 children were enrolled and received ⩾1 dose of ELX/TEZ/IVA; 64 children (97.0%) completed the treatment period (Figure <xref ref-type="fig" rid="F1">1</xref>). Two children discontinued treatment (one adverse event [AE] of erythematous rash and one withdrawal of consent). Baseline characteristics were similar between the <italic>F</italic>/MF (<italic>n</italic> = 37, 56.1%) and <italic>F</italic>/<italic>F</italic> genotype groups (<italic>n</italic> = 29, 43.9%) (Tables <xref rid="T1" ref-type="table">1</xref> and E3).</p>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Patient disposition diagram for part B. *Patient discontinued treatment because of erythematous rash.</p>
                  </caption>
                  <graphic xlink:href="rccm.202102-0509OCf1"/>
                </fig>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Demographics and Clinical Characteristics of the Patients at Baseline in Part B</p>
                  </caption>
                  <!--OASIS TABLE HERE-->
                  <table frame="hsides" rules="groups">
                    <colgroup>
                      <col align="left"/>
                      <col align="center"/>
                      <col align="center"/>
                      <col align="center"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left"> </th>
                        <th colspan="3" align="center">ELX/TEZ/IVA<hr/></th>
                      </tr>
                      <tr>
                        <th align="left"> </th>
                        <th align="center">All Patients (<italic>N</italic> = <italic>66</italic>)<xref ref-type="table-fn" rid="TF3">*</xref></th>
                        <th align="center"><italic>F</italic>/MF (<italic>N</italic> = <italic>37</italic>)</th>
                        <th align="center"><italic>F</italic>/<italic>F</italic> (<italic>N</italic> = <italic>29</italic>)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left">Sex, F, <italic>n</italic> (%)</td>
                        <td align="center">39 (59.1)</td>
                        <td align="center">22 (59.5)</td>
                        <td align="center">17 (58.6)</td>
                      </tr>
                      <tr>
                        <td align="left">Age at baseline, mean (SD), yr</td>
                        <td align="center">9.3 (1.9)</td>
                        <td align="center">9.7 (1.8)</td>
                        <td align="center">8.8 (1.9)</td>
                      </tr>
                      <tr>
                        <td align="left">Race, <italic>n</italic> (%)<sup><xref ref-type="table-fn" rid="TF4">†</xref></sup></td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> White</td>
                        <td align="center">58 (87.9)</td>
                        <td align="center">33 (89.2)</td>
                        <td align="center">25 (86.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Black or African American</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left"> Asian</td>
                        <td align="center">1 (1.5)</td>
                        <td align="center">1 (2.7)</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left"> American Indian or Alaska Native</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left"> Native Hawaiian or other Pacific Islander</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left"> Other</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left"> Not collected per local regulations</td>
                        <td align="center">8 (12.1)</td>
                        <td align="center">4 (10.8)</td>
                        <td align="center">4 (13.8)</td>
                      </tr>
                      <tr>
                        <td align="left">Geographic region, <italic>n</italic> (%)</td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> North America</td>
                        <td align="center">47 (71.2)</td>
                        <td align="center">27 (73.0)</td>
                        <td align="center">20 (69.0)</td>
                      </tr>
                      <tr>
                        <td align="left"> Europe and Australia</td>
                        <td align="center">19 (28.8)</td>
                        <td align="center">10 (27.0)</td>
                        <td align="center">9 (31.0)</td>
                      </tr>
                      <tr>
                        <td align="left">Weight, mean (SD), kg</td>
                        <td align="center">30.0 (7.7)</td>
                        <td align="center">31.4 (7.9)</td>
                        <td align="center">28.2 (7.3)</td>
                      </tr>
                      <tr>
                        <td align="left">Weight distribution, <italic>n</italic> (%)</td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> &lt;30 kg</td>
                        <td align="center">36 (54.5)</td>
                        <td align="center">20 (54.1)</td>
                        <td align="center">16 (55.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> ⩾30 kg</td>
                        <td align="center">30 (45.5)</td>
                        <td align="center">17 (45.9)</td>
                        <td align="center">13 (44.8)</td>
                      </tr>
                      <tr>
                        <td align="left">Weight-for-age <italic>z-</italic>score, mean (SD)</td>
                        <td align="center">−0.22 (0.76)</td>
                        <td align="center">−0.20 (0.87)</td>
                        <td align="center">−0.23 (0.59)</td>
                      </tr>
                      <tr>
                        <td align="left">Height, mean (SD), cm</td>
                        <td align="center">134.1 (12.3)</td>
                        <td align="center">136.9 (12.0)</td>
                        <td align="center">130.4 (11.9)</td>
                      </tr>
                      <tr>
                        <td align="left">Height-for-age <italic>z</italic>-score, mean (SD)</td>
                        <td align="center">−0.11 (0.98)</td>
                        <td align="center">−0.01 (1.03)</td>
                        <td align="center">−0.23 (0.91)</td>
                      </tr>
                      <tr>
                        <td align="left">BMI, mean (SD), kg/m<sup>2</sup></td>
                        <td align="center">16.39 (1.69)</td>
                        <td align="center">16.50 (1.77)</td>
                        <td align="center">16.26 (1.61)</td>
                      </tr>
                      <tr>
                        <td align="left">BMI-for-age <italic>z-</italic>score, mean (SD)</td>
                        <td align="center">−0.16 (0.74)</td>
                        <td align="center">−0.21 (0.84)</td>
                        <td align="center">−0.10 (0.61)</td>
                      </tr>
                      <tr>
                        <td align="left">ppFEV<sub>1</sub>, mean (SD)<sup><xref ref-type="table-fn" rid="TF5">‡</xref></sup></td>
                        <td align="center">88.8 (17.7)</td>
                        <td align="center">89.8 (17.5)</td>
                        <td align="center">87.3 (18.3)</td>
                      </tr>
                      <tr>
                        <td align="left">ppFEV<sub>1</sub> category, <italic>n</italic> (%)</td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> &lt;70</td>
                        <td align="center">10 (15.2)</td>
                        <td align="center">5 (13.5)</td>
                        <td align="center">5 (17.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> ⩾70–⩽90</td>
                        <td align="center">22 (33.3)</td>
                        <td align="center">15 (40.5)</td>
                        <td align="center">7 (24.1)</td>
                      </tr>
                      <tr>
                        <td align="left"> &gt;90</td>
                        <td align="center">30 (45.5)</td>
                        <td align="center">17 (45.9)</td>
                        <td align="center">13 (44.8)</td>
                      </tr>
                      <tr>
                        <td align="left"> Missing data</td>
                        <td align="center">4 (6.1)</td>
                        <td align="center">0</td>
                        <td align="center">4 (13.8)</td>
                      </tr>
                      <tr>
                        <td align="left">Sweat chloride concentration, mean (SD), mmol/L<sup><xref ref-type="table-fn" rid="TF6">§</xref></sup></td>
                        <td align="center">102.2 (9.1)</td>
                        <td align="center">104.4 (7.2)</td>
                        <td align="center">99.3 (10.8)</td>
                      </tr>
                      <tr>
                        <td align="left">CFQ-R respiratory domain score, mean (SD) points<sup><xref ref-type="table-fn" rid="TF7">‖</xref></sup></td>
                        <td align="center">80.3 (15.2)</td>
                        <td align="center">79.1 (17.3)</td>
                        <td align="center">81.8 (12.0)</td>
                      </tr>
                      <tr>
                        <td align="left">LCI<sub>2.5</sub>, mean (SD), units<sup><xref ref-type="table-fn" rid="TF8">¶</xref></sup></td>
                        <td align="center">9.77 (2.68)</td>
                        <td align="center">9.34 (1.82)</td>
                        <td align="center">10.26 (3.36)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TF1">
                      <p><italic>Definition of abbreviations</italic>: BMI = body mass index; CFQ-R = Cystic Fibrosis Questionnaire–Revised; CFTR = cystic fibrosis transmembrane conductance regulator; ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor; <italic>F</italic>/<italic>F</italic> = homozygous for the <italic>F508del-CFTR</italic> mutation; <italic>F</italic>/MF = heterozygous for the <italic>F508del-CFTR</italic> mutation and a minimal function <italic>CFTR</italic> mutation; LCI<sub>2.5</sub> = lung clearance index<sub>2.5</sub>; ppFEV<sub>1</sub> = percentage of predicted FEV<sub>1</sub>.</p>
                    </fn>
                    <fn id="TF2">
                      <p>Baseline was defined as the most recent nonmissing measurement before the first dose of study drug.</p>
                    </fn>
                    <fn id="TF3">
                      <label>*</label>
                      <p>All patients in the full analysis set.</p>
                    </fn>
                    <fn id="TF4">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>The race categories may sum to &gt;100% because each patient was able to indicate more than one race.</p>
                    </fn>
                    <fn id="TF5">
                      <label>
                        <sup>‡</sup>
                      </label>
                      <p><italic>n</italic> = 62 for all patients; <italic>n</italic> = 37 for <italic>F</italic>/MF; <italic>n</italic> = 25 for <italic>F</italic>/<italic>F</italic>.</p>
                    </fn>
                    <fn id="TF6">
                      <label>
                        <sup>§</sup>
                      </label>
                      <p><italic>n</italic> = 62 for all patients; <italic>n</italic> = 36 for <italic>F</italic>/MF; <italic>n</italic> = 26 for <italic>F</italic>/<italic>F</italic>.</p>
                    </fn>
                    <fn id="TF7">
                      <label>
                        <sup>‖</sup>
                      </label>
                      <p><italic>n</italic> = 65 for all patients; <italic>n</italic> = 37 for <italic>F</italic>/MF; <italic>n</italic> = 28 for <italic>F</italic>/<italic>F</italic>. Scores on the CFQ-R range from 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory status.</p>
                    </fn>
                    <fn id="TF8">
                      <label>
                        <sup>¶</sup>
                      </label>
                      <p><italic>n</italic> = 53 for all patients; <italic>n</italic> = 28 for <italic>F</italic>/MF; <italic>n</italic> = 25 for <italic>F</italic>/<italic>F</italic>.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2B">
                <title>Safety and Pharmacokinetics</title>
                <p content-type="flushleft">Safety and tolerability were the primary endpoints for part B of the study. Sixty-five children (98.5%) had AEs, which for most were mild (54.5%) or moderate (42.4%) in severity and generally consistent with manifestations of CF or common childhood infections (Table <xref rid="T2" ref-type="table">2</xref>). The most commonly reported AEs included cough, headache, and pyrexia. One child experienced serious AEs in the study; these were concurrent events of rhinovirus infection, metapneumovirus infection, and pneumonia (which was resolved with intravenous antibiotics).</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Adverse Events in Part B</p>
                  </caption>
                  <!--OASIS TABLE HERE-->
                  <table frame="hsides" rules="groups">
                    <colgroup>
                      <col align="left"/>
                      <col align="center"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left"> </th>
                        <th align="center">ELX/TEZ/IVA (<italic>N</italic> = <italic>66</italic>)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left">Any AE</td>
                        <td align="center">65 (98.5)</td>
                      </tr>
                      <tr>
                        <td align="left">AE by maximum relatedness<xref ref-type="table-fn" rid="TF12">*</xref></td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> Not related</td>
                        <td align="center">16 (24.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Unlikely related</td>
                        <td align="center">16 (24.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Possibly related</td>
                        <td align="center">29 (43.9)</td>
                      </tr>
                      <tr>
                        <td align="left"> Related</td>
                        <td align="center">4 (6.1)</td>
                      </tr>
                      <tr>
                        <td align="left">AE by maximum severity<xref ref-type="table-fn" rid="TF12">*</xref></td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> Mild</td>
                        <td align="center">36 (54.5)</td>
                      </tr>
                      <tr>
                        <td align="left"> Moderate</td>
                        <td align="center">28 (42.4)</td>
                      </tr>
                      <tr>
                        <td align="left"> Severe</td>
                        <td align="center">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left">Serious AE</td>
                        <td align="center">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left">AE leading to death</td>
                        <td align="center">0</td>
                      </tr>
                      <tr>
                        <td align="left">AE leading to discontinuation</td>
                        <td align="center">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left">AE leading to interruption</td>
                        <td align="center">1 (1.5)<sup><xref ref-type="table-fn" rid="TF13">†</xref></sup></td>
                      </tr>
                      <tr>
                        <td align="left">Most common AEs<sup><xref ref-type="table-fn" rid="TF14">‡</xref></sup></td>
                        <td align="center"> </td>
                      </tr>
                      <tr>
                        <td align="left"> Cough</td>
                        <td align="center">28 (42.4)</td>
                      </tr>
                      <tr>
                        <td align="left"> Headache</td>
                        <td align="center">16 (24.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Pyrexia</td>
                        <td align="center">14 (21.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Oropharyngeal pain</td>
                        <td align="center">12 (18.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Upper respiratory tract infection</td>
                        <td align="center">11 (16.7)</td>
                      </tr>
                      <tr>
                        <td align="left"> Nasal congestion</td>
                        <td align="center">10 (15.2)</td>
                      </tr>
                      <tr>
                        <td align="left"> Rash</td>
                        <td align="center">8 (12.1)</td>
                      </tr>
                      <tr>
                        <td align="left"> Abdominal pain</td>
                        <td align="center">8 (12.1)</td>
                      </tr>
                      <tr>
                        <td align="left"> Rhinorrhea</td>
                        <td align="center">8 (12.1)</td>
                      </tr>
                      <tr>
                        <td align="left"> Viral upper respiratory tract infection</td>
                        <td align="center">8 (12.1)</td>
                      </tr>
                      <tr>
                        <td align="left"> Alanine aminotransferase increased</td>
                        <td align="center">7 (10.6)</td>
                      </tr>
                      <tr>
                        <td align="left"> Diarrhea</td>
                        <td align="center">7 (10.6)</td>
                      </tr>
                      <tr>
                        <td align="left"> Influenza</td>
                        <td align="center">7 (10.6)</td>
                      </tr>
                      <tr>
                        <td align="left"> Vomiting</td>
                        <td align="center">7 (10.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TF9">
                      <p><italic>Definition of abbreviations</italic>: AE = adverse event; ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor.</p>
                    </fn>
                    <fn id="TF10">
                      <p>Data are presented as <italic>n</italic> (%).</p>
                    </fn>
                    <fn id="TF11">
                      <p>A patient with multiple events within a category was counted only once in that category.</p>
                    </fn>
                    <fn id="TF12">
                      <label>*</label>
                      <p>Relatedness to the trial regimen and severity were determined by the investigator observing the event.</p>
                    </fn>
                    <fn id="TF13">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>The one AE leading to study drug interruption was because of diarrhea, vomiting, and fever.</p>
                    </fn>
                    <fn id="TF14">
                      <label>
                        <sup>‡</sup>
                      </label>
                      <p>Only AEs that occurred in ⩾10% of the patients are listed; listing is according to the preferred term (Medical Dictionary for Regulatory Activities version 23.0).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>On the basis of previous experience with ELX/TEZ/IVA, including the phase 3 trials (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>), data related to aminotransferases, rash events, creatine kinase, and blood pressure were reviewed. Elevated levels of alanine aminotransferase and/or aspartate aminotransferase that were greater than three times the upper limit of the age-specific normal range occurred in seven children (10.6%); among these, only one child (1.5%) had an elevation that was greater than five times the upper limit, and no child had an elevation that was greater than eight times the upper limit (Table E4). No children had an elevated aminotransferase level greater than three times the upper limit of the normal range concurrent with an elevated bilirubin level greater than two times the upper limit of the normal range. Seven children had AEs of transaminase elevations, all of which were mild or moderate in severity. There were no study drug interruptions or discontinuations due to elevated transaminases.</p>
                <p>Sixteen children (24.2%) had rash events (Table E5). Rash events constitute a group AE term that includes the preferred term of rash (Table <xref rid="T2" ref-type="table">2</xref>) and other rash-related preferred terms (e.g., rash erythematous, rash maculopapular, rash papular, skin exfoliation, and urticaria). All rash events were mild or moderate in severity. Among these 16 children, 1 child had an erythematous rash that developed after the first dose of ELX/TEZ/IVA and led to study drug discontinuation; the rash was moderate in severity and resolved 2 days after study drug discontinuation. All other rash events resolved without change in study drug dosing. For eight of the children, the rash events were assessed as unlikely to be related or not related to the study drug. Of the remaining children with rash events, four had associated symptoms suggestive of an alternative etiology (e.g., concurrent infection or heat rash).</p>
                <p>No children had creatine kinase levels greater than five times the upper limit of the age-specific normal range (Table E6), and two children had AEs related to creatine kinase. The mean change from baseline for systolic blood pressure through 24 weeks of ELX/TEZ/IVA treatment ranged from −1.4 mm Hg to 0.4 mm Hg, and that for diastolic blood pressure ranged from −0.3 mm Hg to 1.0 mm Hg (Table E7); no AEs related to blood pressure were reported. There were no relevant safety findings in other clinical or laboratory assessments.</p>
                <p>Preliminary analysis of PK data from part A (online supplement) confirmed the planned part B dosing scheme. In part B, definitive population PK analyses for 6- through 11-year-old children with CF revealed that the area under the concentration-versus-time curve (AUC) values for ELX, TEZ, and IVA were within the range of exposures previously seen in those ⩾12 years of age (Figure <xref ref-type="fig" rid="F2">2</xref>), as were the mean observed trough and peak concentrations. These PK simulations confirmed that 30 kg was the optimal weight threshold for the transition from 50% of the adult daily dose to the full adult daily dose of ELX/TEZ/IVA.</p>
                <fig id="F2" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Pharmacokinetic exposure simulation. For each boxplot, the median is represented by a horizontal line, and the interquartile range is represented by the box. The whiskers mark the largest and smallest values within 1.5 × interquartile range. Dots represent individual empirical Bayes AUC estimate (EBE) values. In each panel, the dashed horizontal line represents the median of the ⩾18 years AUC values, and the gray shaded area indicates the 5th and 95th percentiles of the ⩾18 years AUC values. The EBE values for 6–11 years are from part B of this study. The EBE values for ⩾12 years are from studies 445-102 and 445-103 (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). AUC = area under the concentration-versus-time curve; AUC<sub>0–12</sub> = area under the concentration-versus-time curve (0–12 h after dose); AUC<sub>0–24</sub> = area under the concentration-versus-time curve (0–24 h after dose); ELX = elexacaftor; IVA = ivacaftor; TEZ = tezacaftor.</p>
                  </caption>
                  <graphic xlink:href="rccm.202102-0509OCf2"/>
                </fig>
              </sec>
              <sec id="s2C">
                <title>Efficacy</title>
                <sec id="s2C1">
                  <title>Overall</title>
                  <p content-type="flushleft">Treatment with ELX/TEZ/IVA led to a mean absolute change from a baseline of 10.2 percentage points in ppFEV<sub>1</sub> through Week 24 (95% confidence interval [CI], 7.9 to 12.6) (Table <xref rid="T3" ref-type="table">3</xref>), with robust improvements seen as soon as 2 weeks after initiation (Figure <xref ref-type="fig" rid="F3">3A</xref>). Similarly, rapid and sustained improvements were seen in CFQ-R respiratory domain scores (mean absolute change from baseline of 7.0 points; 95% CI, 4.7 to 9.2) (Figure <xref ref-type="fig" rid="F3">3B</xref> and Table <xref rid="T3" ref-type="table">3</xref>), LCI<sub>2.5</sub> (mean absolute change from baseline of −1.71 units; 95% CI, −2.11 to −1.30) (Figure <xref ref-type="fig" rid="F3">3C</xref> and Table <xref rid="T3" ref-type="table">3</xref>), and sweat chloride concentration (mean absolute change from baseline of −60.9 mmol/L through Week 24; 95% CI, −63.7 to −58.2) (Figure <xref ref-type="fig" rid="F3">3D</xref> and Table <xref rid="T3" ref-type="table">3</xref>). BMI, BMI-for-age <italic>z</italic>-score, weight, weight-for-age <italic>z</italic>-score, and height increased over the 24-week treatment period without reaching a plateau, whereas height-for-age <italic>z</italic>-score was maintained (Figure <xref ref-type="fig" rid="F4">4</xref> and Table E8).</p>
                  <fig id="F3" orientation="portrait" position="float">
                    <label>Figure 3.</label>
                    <caption>
                      <p>Efficacy results, by visit, in part B. (<italic>A</italic>) Absolute change from baseline at each visit in ppFEV<sub>1</sub>. (<italic>B</italic>) Absolute change from baseline at each visit in the respiratory domain score on the CFQ-R, child’s version; scores are normalized to a 100-point range, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms. (<italic>C</italic>) Absolute change from baseline at each visit in LCI<sub>2.5</sub>. (<italic>D</italic>) Absolute change from baseline at each visit in sweat chloride concentration; a reduction indicates improvement in CFTR (cystic fibrosis transmembrane conductance regulator) function. Data are least squares means based on a mixed-effects model for repeated measures, and error bars indicate SEMs; the dashed line indicates no change from baseline. Sample size shown under each <italic>x</italic>-axis is the number of patients at the time point with evaluable in-clinic data. CFQ-R = Cystic Fibrosis Questionnaire–Revised; LCI<sub>2.5</sub> = lung clearance index<sub>2.5</sub>; ppFEV<sub>1</sub> = percentage of predicted FEV<sub>1</sub>.</p>
                    </caption>
                    <graphic xlink:href="rccm.202102-0509OCf3"/>
                  </fig>
                  <fig id="F4" orientation="portrait" position="float">
                    <label>Figure 4.</label>
                    <caption>
                      <p>Absolute change from baseline at each visit in (<italic>A</italic>) BMI, (<italic>B</italic>) BMI-for-age <italic>z</italic>-score, (<italic>C</italic>) weight, (<italic>D</italic>) weight-for-age <italic>z</italic>-score, (<italic>E</italic>) height, and (<italic>F</italic>) height-for-age <italic>z</italic>-score in part B. Data are least squares means based on a mixed-effects model for repeated measures, and error bars indicate SEMs; the dashed line indicates no change from baseline. Sample size shown under each <italic>x</italic>-axis is the number of patients at the time point with evaluable in-clinic data. BMI = body mass index.</p>
                    </caption>
                    <graphic xlink:href="rccm.202102-0509OCf4"/>
                  </fig>
                  <table-wrap id="T3" orientation="portrait" position="float">
                    <label>Table 3.</label>
                    <caption>
                      <p>Secondary Efficacy Endpoints from Part B</p>
                    </caption>
                    <!--OASIS TABLE HERE-->
                    <table frame="hsides" rules="groups">
                      <colgroup>
                        <col align="left"/>
                        <col align="center"/>
                        <col align="center"/>
                        <col align="center"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left"> </th>
                          <th colspan="3" align="center">ELX/TEZ/IVA<hr/></th>
                        </tr>
                        <tr>
                          <th align="left"> </th>
                          <th align="center">All Patients (<italic>N</italic> = <italic>66</italic>)<xref ref-type="table-fn" rid="TF17">*</xref></th>
                          <th align="center"><italic>F</italic>/MF (<italic>N</italic> = <italic>37</italic>)</th>
                          <th align="center"><italic>F</italic>/<italic>F</italic> (<italic>N</italic> = <italic>29</italic>)</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left">ppFEV<sub>1</sub>, percentage points</td>
                          <td align="left"> </td>
                          <td align="left"> </td>
                          <td align="center"> </td>
                        </tr>
                        <tr>
                          <td align="left"> Baseline, mean (SD)<sup><xref ref-type="table-fn" rid="TF18">†</xref></sup></td>
                          <td align="center">88.8 (17.7)</td>
                          <td align="center">89.8 (17.5)</td>
                          <td align="center">87.3 (18.3)</td>
                        </tr>
                        <tr>
                          <td align="left"> Absolute change through Week 24, LS mean (95% CI)</td>
                          <td align="center">10.2 (7.9 to 12.6)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">9.1 (6.3 to 11.9)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">11.2 (7.2 to 15.2)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                        </tr>
                        <tr>
                          <td align="left">CFQ-R respiratory domain score, points</td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                        </tr>
                        <tr>
                          <td align="left"> Baseline, mean (SD)<sup><xref ref-type="table-fn" rid="TF18">†</xref></sup></td>
                          <td align="center">80.3 (15.2)</td>
                          <td align="center">79.1 (17.3)</td>
                          <td align="center">81.8 (12.0)</td>
                        </tr>
                        <tr>
                          <td align="left"> Absolute change through Week 24, LS mean (95% CI)</td>
                          <td align="center">7.0 (4.7 to 9.2)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">6.9 (3.2 to 10.6)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">7.0 (3.9 to 10.1)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                        </tr>
                        <tr>
                          <td align="left">LCI<sub>2.5</sub>, units</td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                        </tr>
                        <tr>
                          <td align="left"> Baseline, mean (SD)<sup><xref ref-type="table-fn" rid="TF18">†</xref></sup></td>
                          <td align="center">9.77 (2.68)</td>
                          <td align="center">9.34 (1.82)</td>
                          <td align="center">10.26 (3.36)</td>
                        </tr>
                        <tr>
                          <td align="left"> Absolute change through Week 24, LS mean (95% CI)</td>
                          <td align="center">−1.71 (−2.11 to −1.30)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">−1.72 (−2.11 to −1.33)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">−1.64 (−2.34 to −0.94)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                        </tr>
                        <tr>
                          <td align="left">Sweat chloride, mmol/L</td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                          <td align="center"> </td>
                        </tr>
                        <tr>
                          <td align="left"> Baseline, mean (SD)<sup><xref ref-type="table-fn" rid="TF18">†</xref></sup></td>
                          <td align="center">102.2 (9.1)</td>
                          <td align="center">104.4 (7.2)</td>
                          <td align="center">99.3 (10.8)</td>
                        </tr>
                        <tr>
                          <td align="left"> Absolute change through Week 24, LS mean (95% CI)</td>
                          <td align="center">−60.9 (−63.7 to −58.2)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">−55.1 (−59.0 to −51.2)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                          <td align="center">−70.4 (−75.6 to −65.3)<sup><xref ref-type="table-fn" rid="TF19">‡</xref></sup></td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="TF15">
                        <p><italic>Definition of abbreviations</italic>: CFQ-R = Cystic Fibrosis Questionnaire–Revised; CFTR = cystic fibrosis transmembrane conductance regulator; CI = confidence interval; ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor; <italic>F</italic>/<italic>F</italic> = homozygous for the <italic>F508del-CFTR</italic> mutation; <italic>F</italic>/MF = heterozygous for the <italic>F508del-CFTR</italic> mutation and a minimal function <italic>CFTR</italic> mutation; LCI<sub>2.5</sub> = lung clearance index<sub>2.5</sub>; LS = least squares; ppFEV<sub>1</sub> = percentage of predicted FEV<sub>1</sub>.</p>
                      </fn>
                      <fn id="TF16">
                        <p><italic>N</italic> indicates the total number of patients in each population; LS means were based on mixed-effects model for repeated measures; absolute changes through Week 24 were averages of the visits between Weeks 4 and 24 (inclusive).</p>
                      </fn>
                      <fn id="TF17">
                        <label>
                          <sup>*</sup>
                        </label>
                        <p>All patients in the full analysis set.</p>
                      </fn>
                      <fn id="TF18">
                        <label>
                          <sup>†</sup>
                        </label>
                        <p>Baseline was defined as the most recent nonmissing measurement before the first dose of study drug.</p>
                      </fn>
                      <fn id="TF19">
                        <label>
                          <sup>‡</sup>
                        </label>
                        <p>Nominal <italic>P</italic> value &lt;0.001.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="s2C2">
                  <title>Subgroup analysis</title>
                  <p>The <italic>F</italic>/MF and <italic>F</italic>/<italic>F</italic> genotype groups showed similar improvements in ppFEV<sub>1</sub>, CFQ-R respiratory domain score, and LCI<sub>2.5</sub> (Table <xref rid="T3" ref-type="table">3</xref>). In contrast, the decrease in mean sweat chloride concentration was greater in the <italic>F</italic>/<italic>F</italic> genotype group (−70.4 mmol/L; 95% CI, −75.6 to −65.3) than in the <italic>F</italic>/MF genotype group (−55.1 mmol/L; 95% CI, −59.0 to −51.2) (Table <xref rid="T3" ref-type="table">3</xref>). The distribution of individual changes from baseline in sweat chloride concentration showed clear separation by genotype, consistent with greater reductions among those with the <italic>F</italic>/<italic>F</italic> genotype (Figure E2). At baseline, no children had sweat chloride concentrations below the diagnostic threshold for CF of 60 mmol/L (Table E9) (<xref rid="B5" ref-type="bibr">5</xref>). For both the <italic>F</italic>/MF and <italic>F</italic>/<italic>F</italic> genotype groups, mean sweat chloride concentrations fell to below the diagnostic threshold of 60 mmol/L by Day 15, and for the <italic>F</italic>/<italic>F</italic> group, concentrations approached 30 mmol/L (Figure E3). Reductions in sweat chloride concentrations to &lt;60 mmol/L and &lt;30 mmol/L in response to ELX/TEZ/IVA treatment were assessed as a <italic>post hoc</italic> analysis and found to be more prevalent among children with the <italic>F</italic>/<italic>F</italic> genotype (100.0% and 42.9%, respectively) as compared with children with <italic>F</italic>/MF genotypes (80.0% and 5.7%, respectively) (Figure <xref ref-type="fig" rid="F5">5</xref> and Table E9).</p>
                  <fig id="F5" orientation="portrait" position="float">
                    <label>Figure 5.</label>
                    <caption>
                      <p>Responder analysis for sweat chloride concentration by genotype group in part B. The percentage of children in each genotype group with sweat chloride concentrations &lt;60 mmol/L or &lt;30 mmol/L through Week 24 is shown. No children had sweat chloride concentrations &lt;60 mmol/L at baseline. Percentages were calculated by dividing <italic>n</italic> (the number of patients with sweat chloride concentration below the indicated threshold) by N1, where N1 is the number of patients with evaluable data. Patients with missing data were considered missing at random and were not counted in the denominator. <italic>F</italic>/<italic>F</italic> = homozygous for the <italic>F508del-CFTR</italic> mutation; <italic>F</italic>/MF = heterozygous for the <italic>F508del-CFTR</italic> mutation and a minimal function <italic>CFTR</italic> mutation.</p>
                    </caption>
                    <graphic xlink:href="rccm.202102-0509OCf5"/>
                  </fig>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p content-type="flushleft">We evaluated the safety and efficacy of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one <italic>F508del-CFTR</italic> allele, the youngest patients treated with a three-drug CFTR modulator regimen to date. Treatment with ELX/TEZ/IVA was generally safe and well tolerated; the most common reported AEs were consistent with manifestations of CF or common childhood infections. The safety profile in children 6 through 11 years of age was consistent with the established profile in patients ⩾12 years of age with CF.</p>
              <p>As ELX/TEZ/IVA is likely to be a long-term therapy in children with CF, understanding the incidence of laboratory and clinical events that may occur during drug exposure is important. Children in this study were found to have an incidence of aminotransferase elevation that was similar to the incidence previously observed in patients ⩾12 years of age treated with ELX/TEZ/IVA for 24 weeks (<xref rid="B13" ref-type="bibr">13</xref>) and in children aged 6 through 11 years treated with TEZ/IVA for 24 weeks (<xref rid="B15" ref-type="bibr">15</xref>). The rashes observed during this study were mild to moderate in severity, and the vast majority were transient and resolved with continued ELX/TEZ/IVA treatment.</p>
              <p>Pharmacokinetic and clinical evaluation confirmed the appropriateness of a dose that is 50% of the adult daily dose of ELX/TEZ/IVA for children 6 through 11 years of age who are &lt;30 kg and of the full adult dose for those ⩾30 kg. For these weight subgroups of children aged 6 through 11 years, exposures to ELX, TEZ, and IVA were within similar AUC ranges as those seen in patients ⩾12 years of age with CF.</p>
              <p>Children in this study had substantially higher mean baseline lung function (ppFEV<sub>1</sub>, 88.8 percentage points) and CFQ-R respiratory domain scores (80.3 points) than seen in the phase 3 pivotal studies in adults and adolescents (ppFEV<sub>1</sub>, ∼62 percentage points; CFQ-R respiratory domain scores, ∼70 points) (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Despite these higher baselines, ELX/TEZ/IVA treatment of these children for 24 weeks led to a 10.2–percentage point improvement in mean ppFEV<sub>1</sub> and a 7.0-point improvement in mean CFQ-R respiratory domain score. Rapid improvements in ppFEV<sub>1</sub> were seen within 2 weeks of ELX/TEZ/IVA initiation, consistent with results from other CFTR modulator studies (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr"/>–<xref rid="B19" ref-type="bibr">19</xref>). The improvements in ppFEV<sub>1</sub> were corroborated by rapid and sustained improvements in LCI<sub>2.5</sub>, a measure of ventilation inhomogeneity that may be more sensitive than spirometry in detecting lung function changes during childhood. LCI<sub>2.5</sub> has also previously been shown to improve with CFTR modulator treatment in children homozygous for the <italic>F508del</italic> allele (<xref rid="B20" ref-type="bibr">20</xref>). ELX/TEZ/IVA treatment over 24 weeks led to an LCI<sub>2.5</sub> improvement of −1.71 units. In contrast, a longitudinal natural history study of children with CF not being treated with CFTR modulators showed an increase in LCI<sub>2.5</sub> of 0.21 units per year (higher values of LCI<sub>2.5</sub> reflect worse lung function) in children 6 through 11 years of age (<xref rid="B21" ref-type="bibr">21</xref>). Registry data have shown that long-term use of IVA slows lung function decline and lowers the risk of death (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Thus, early initiation of ELX/TEZ/IVA in children with CF is likely to improve lung function and minimize worsening of ppFEV<sub>1</sub> and LCI<sub>2.5</sub> associated with disease progression (<xref rid="B7" ref-type="bibr">7</xref>).</p>
              <p>Maintaining or improving nutritional status is associated with better lung function and increased survival rates in patients with CF (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). During this 24-week study, increases in both BMI-for-age and weight-for-age <italic>z</italic>-scores were seen, whereas height-for-age <italic>z</italic>-score was maintained. The improvements in BMI and weight, as well as their corresponding for-age <italic>z</italic>-scores, were greater than those observed in a previous 24-week trial of a dual-combination modulator regimen in children who were 6 through 11 years old and homozygous for <italic>F508del-CFTR</italic> (<xref rid="B16" ref-type="bibr">16</xref>), indicating ELX/TEZ/IVA may confer nutritional benefits greater than those of CFTR modulators that are currently approved for use in children.</p>
              <p>Beyond respiratory and nutritional outcomes, changes in sweat chloride concentration provide a direct indicator of systemic CFTR function (<xref rid="B3" ref-type="bibr">3</xref>). In this study, ELX/TEZ/IVA treatment of children with CF led to greater improvements in sweat chloride than those previously seen in adults and adolescents (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Children homozygous for <italic>F508del-CFTR</italic> had a greater decrease in sweat chloride than those with a single <italic>F508del-CFTR</italic> allele, consistent with genotype-related differences seen in adolescents and adults (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>) and likely attributable to increased abundance of the F508del-CFTR protein that can be targeted for CFTR modulation in homozygotes. Reductions of sweat chloride concentrations to &lt;60 mmol/L (the threshold for definitive diagnosis of CF [<xref rid="B5" ref-type="bibr">5</xref>]) and to &lt;30 mmol/L (matching levels generally seen in the population of asymptomatic carriers with a single mutant <italic>CFTR</italic> allele [<xref rid="B26" ref-type="bibr">26</xref>], and a level below which a diagnosis of CF is unlikely [<xref rid="B27" ref-type="bibr">27</xref>]) were more prevalent in children with the <italic>F</italic>/<italic>F</italic> genotype than in those with <italic>F</italic>/MF genotypes. In a natural history study, sweat chloride concentrations &lt;60 mmol/L were associated with improved survival in patients with CF (<xref rid="B28" ref-type="bibr">28</xref>), suggesting that substantial improvements in sweat chloride in response to CFTR modulator therapy may presage improvements in long-term clinical outcomes.</p>
              <p>Because this study did not include a placebo group, the incidence of safety events attributable to the underlying disease process was not ascertained. Furthermore, the small sample size of this study limited the ability to detect uncommon and rare AEs. However, placebo groups in trials with similar populations provide perspective on safety and tolerability (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B29" ref-type="bibr">29</xref>), and the safety of ELX/TEZ/IVA is well established in children and adolescents ≥12 years of age (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). In addition, the ongoing 96-week open-label extension study (NCT04183790) will assess the long-term safety and durability of efficacy of ELX/TEZ/IVA in children who began treatment at 6 through 11 years of age. Another potential limitation of this and other CF clinical studies is that patients from minority groups are less likely to be eligible because the <italic>F508del-CFTR</italic> mutation that was the focus of this study is less common in these populations (<xref rid="B30" ref-type="bibr">30</xref>).</p>
              <p>As this study overlapped with the early months of the SARS-CoV-2 pandemic, a global protocol addendum was implemented that enabled in-home assessments. The safety results reported here were based on both in-clinic and in-home safety assessments. However, only a small number of in-home efficacy assessments were performed, and the efficacy results presented here were based solely on in-clinic assessments. Additional sensitivity analyses that pooled in-clinic and in-home efficacy data gave results consistent with the main efficacy analyses.</p>
              <p>The efficacy and safety of ELX/TEZ/IVA in children are consistent with those reported in the controlled phase 3 pivotal studies in adults and adolescents with CF (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>) and further confirm the ability of ELX/TEZ/IVA to modulate a single <italic>F508del-CFTR</italic> allele in patients with CF. Taken together, these results strongly support the use of ELX/TEZ/IVA in children 6 through 11 years of age with at least one <italic>F508del-CFTR</italic> allele to provide effective treatment of CF at an early stage of disease when serious long-term complications may be averted. </p>
            </sec>
          </body>
          <back>
            <ack>
              <sec>
                <title>Acknowledgment</title>
                <p>The authors thank the patients and their families for participating in this trial; all site trial investigators and coordinators; the Australian, North American, and European Lung Clearance Index Central Over-Reading Centres teams for their contributions to the trial; the Cystic Fibrosis Foundation Therapeutics Development Network and the European Cystic Fibrosis Society Clinical Trials Network for their support of the trial sites; Emily Poulin, Ph.D., an employee of Vertex Pharmaceuticals, who may own stock or stock options in the company, for providing editorial coordination and support; Fanuel Hagos, Ph.D., an employee of Vertex Pharmaceuticals, who may own stock or stock options in the company, for providing support with the clinical pharmacological analysis; and Nathan Blow, Ph.D., of Vertex Pharmaceuticals, who may own stock or stock options in the company, and JoAnna Anderson, Ph.D., CMPP, of ArticulateScience LLC for providing editorial assistance under the guidance of the authors and with support from Vertex Pharmaceuticals.</p>
              </sec>
            </ack>
            <fn-group>
              <fn id="FN1" fn-type="supported-by">
                <p>Supported by Vertex Pharmaceuticals.</p>
              </fn>
              <fn id="FN2" fn-type="con">
                <p>Author Contributions: The study sponsor (Vertex Pharmaceuticals Incorporated) designed the protocol in collaboration with the academic authors. Site investigators collected the data, which were analyzed by the sponsor. All authors had full access to the study data. E.T.Z., J.L.T.-C., C.E.W., and S.A.M. developed the initial draft of the manuscript, with writing assistance from the sponsor. All authors participated in subsequent revisions. All authors approved the final version submitted for publication.</p>
              </fn>
              <fn id="FN3" fn-type="other">
                <p>
                  <ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.1164/rccm.202104-0850ED">This article has a related editorial.</ext-link>
                </p>
              </fn>
              <fn id="FN4" fn-type="other">
                <p>This article has an online supplement, which is accessible from this issue’s table of contents at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
              <fn id="FN5" fn-type="doi">
                <p>Originally Published in Press as DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.202102-0509OC">10.1164/rccm.202102-0509OC</ext-link> on March 18, 2021</p>
              </fn>
              <fn id="FN6" fn-type="financial-disclosure">
                <p><underline><ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.202102-0509OC/suppl_file/disclosures.pdf"><bold>Author disclosures</bold></ext-link></underline> are available with the text of this article at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Riordan</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Rommens</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Kerem</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Alon</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rozmahel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Grzelczak</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA</article-title>
                  <source>
                    <italic>Science</italic>
                  </source>
                  <year>1989</year>
                  <volume>245</volume>
                  <fpage>1066</fpage>
                  <lpage>1073</lpage>
                  <pub-id pub-id-type="pmid">2475911</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="book">
                  <collab>Cystic Fibrosis Foundation</collab>
                  <publisher-loc>Bethesda, MD</publisher-loc>
                  <publisher-name>Cystic Fibrosis Foundation</publisher-name>
                  <year>2020</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf">https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Elborn</surname>
                      <given-names>JS.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cystic fibrosis</article-title>
                  <source>
                    <italic>Lancet</italic>
                  </source>
                  <year>2016</year>
                  <volume>388</volume>
                  <fpage>2519</fpage>
                  <lpage>2531</lpage>
                  <pub-id pub-id-type="pmid">27140670</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bell</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Mall</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Gutierrez</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Macek</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Madge</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>JC</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>The future of cystic fibrosis care: a global perspective</article-title>
                  <source>
                    <italic>Lancet Respir Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>8</volume>
                  <fpage>65</fpage>
                  <lpage>124</lpage>
                  <pub-id pub-id-type="pmid">31570318</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ratjen</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bell</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Goss</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Quittner</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Bush</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cystic fibrosis</article-title>
                  <source>
                    <italic>Nat Rev Dis Primers</italic>
                  </source>
                  <year>2015</year>
                  <volume>1</volume>
                  <fpage>15010</fpage>
                  <pub-id pub-id-type="pmid">27189798</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlüter</surname>
                      <given-names>DK</given-names>
                    </name>
                    <name>
                      <surname>Griffiths</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Adam</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Akbari</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Heaven</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Paranjothy</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales</article-title>
                  <source>
                    <italic>Thorax</italic>
                  </source>
                  <year>2019</year>
                  <volume>74</volume>
                  <fpage>447</fpage>
                  <lpage>454</lpage>
                  <pub-id pub-id-type="pmid">30026297</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>VanDevanter</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Kahle</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>O’Sullivan</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Sikirica</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hodgkins</surname>
                      <given-names>PS.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment</article-title>
                  <source>
                    <italic>J Cyst Fibros</italic>
                  </source>
                  <year>2016</year>
                  <volume>15</volume>
                  <fpage>147</fpage>
                  <lpage>157</lpage>
                  <pub-id pub-id-type="pmid">26454351</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farrell</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Kosorok</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Rock</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Laxova</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zeng</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>HC</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>Wisconsin Cystic Fibrosis Neonatal Screening Study Group</collab>
                  <article-title>Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth</article-title>
                  <source>
                    <italic>Pediatrics</italic>
                  </source>
                  <year>2001</year>
                  <volume>107</volume>
                  <fpage>1</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="pmid">11134427</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lopes-Pacheco</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine</article-title>
                  <source>
                    <italic>Front Pharmacol</italic>
                  </source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>1662</fpage>
                  <pub-id pub-id-type="pmid">32153386</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boyle</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>De Boeck</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect</article-title>
                  <source>
                    <italic>Lancet Respir Med</italic>
                  </source>
                  <year>2013</year>
                  <volume>1</volume>
                  <fpage>158</fpage>
                  <lpage>163</lpage>
                  <pub-id pub-id-type="pmid">24429096</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mall</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Mayer-Hamblett</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>SM.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>201</volume>
                  <fpage>1193</fpage>
                  <lpage>1208</lpage>
                  <pub-id pub-id-type="pmid">31860331</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heijerman</surname>
                      <given-names>HGM</given-names>
                    </name>
                    <name>
                      <surname>McKone</surname>
                      <given-names>EF</given-names>
                    </name>
                    <name>
                      <surname>Downey</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Van Braeckel</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Tullis</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX17-445-103 Trial Group</collab>
                  <article-title>Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial</article-title>
                  <source>
                    <italic>Lancet</italic>
                  </source>
                  <year>2019</year>
                  <volume>394</volume>
                  <fpage>1940</fpage>
                  <lpage>1948</lpage>
                  <pub-id pub-id-type="pmid">31679946</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Middleton</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Mall</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Dřevínek</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lands</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>McKone</surname>
                      <given-names>EF</given-names>
                    </name>
                    <name>
                      <surname>Polineni</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX17-445-102 Study Group</collab>
                  <article-title>Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2019</year>
                  <volume>381</volume>
                  <fpage>1809</fpage>
                  <lpage>1819</lpage>
                  <pub-id pub-id-type="pmid">31697873</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Wainwright</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Canny</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Chilvers</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Howenstine</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Munck</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX08-770-103 (ENVISION) Study Group</collab>
                  <article-title>Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2013</year>
                  <volume>187</volume>
                  <fpage>1219</fpage>
                  <lpage>1225</lpage>
                  <pub-id pub-id-type="pmid">23590265</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walker</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Flume</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>McNamara</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Solomon</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chilvers</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chmiel</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX15-661-113 Investigator Group</collab>
                  <article-title>A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis</article-title>
                  <source>
                    <italic>J Cyst Fibros</italic>
                  </source>
                  <year>2019</year>
                  <volume>18</volume>
                  <fpage>708</fpage>
                  <lpage>713</lpage>
                  <pub-id pub-id-type="pmid">31253540</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Milla</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Ratjen</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Marigowda</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Waltz</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Rosenfeld</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <collab>VX13-809-011 Part B Investigator Group</collab>
                  <article-title>Lumacaftor/ivacaftor in patients aged 6–11 years with cystic fibrosis and homozygous for F508del-CFTR</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2017</year>
                  <volume>195</volume>
                  <fpage>912</fpage>
                  <lpage>920</lpage>
                  <pub-id pub-id-type="pmid">27805836</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramsey</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>McElvaney</surname>
                      <given-names>NG</given-names>
                    </name>
                    <name>
                      <surname>Tullis</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bell</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Dřevínek</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX08-770-102 Study Group</collab>
                  <article-title>A CFTR potentiator in patients with cystic fibrosis and the G551D mutation</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2011</year>
                  <volume>365</volume>
                  <fpage>1663</fpage>
                  <lpage>1672</lpage>
                  <pub-id pub-id-type="pmid">22047557</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor-Cousar</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Munck</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>McKone</surname>
                      <given-names>EF</given-names>
                    </name>
                    <name>
                      <surname>van der Ent</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Moeller</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Simard</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2017</year>
                  <volume>377</volume>
                  <fpage>2013</fpage>
                  <lpage>2023</lpage>
                  <pub-id pub-id-type="pmid">29099344</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wainwright</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Elborn</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Ramsey</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Marigowda</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Cipolli</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>TRAFFIC Study Group</collab>
                  <collab>TRANSPORT Study Group</collab>
                  <article-title>Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>373</volume>
                  <fpage>220</fpage>
                  <lpage>231</lpage>
                  <pub-id pub-id-type="pmid">25981758</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ratjen</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hug</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Marigowda</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Stanojevic</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX14-809-109 investigator group</collab>
                  <article-title>Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial</article-title>
                  <source>
                    <italic>Lancet Respir Med</italic>
                  </source>
                  <year>2017</year>
                  <volume>5</volume>
                  <fpage>557</fpage>
                  <lpage>567</lpage>
                  <pub-id pub-id-type="pmid">28606620</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frauchiger</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Binggeli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yammine</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Spycher</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Krüger</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ramsey</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Longitudinal course of clinical lung clearance index in children with cystic fibrosis</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <pub-id pub-id-type="doi">10.1183/13993003.02686-2020</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bessonova</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Volkova</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Higgins</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bengtsson</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Simard</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor</article-title>
                  <source>
                    <italic>Thorax</italic>
                  </source>
                  <year>2018</year>
                  <volume>73</volume>
                  <fpage>731</fpage>
                  <lpage>740</lpage>
                  <pub-id pub-id-type="pmid">29748252</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sawicki</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>McKone</surname>
                      <given-names>EF</given-names>
                    </name>
                    <name>
                      <surname>Pasta</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Millar</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Wagener</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>192</volume>
                  <fpage>836</fpage>
                  <lpage>842</lpage>
                  <pub-id pub-id-type="pmid">26132840</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Konstan</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Butler</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Wohl</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Stoddard</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Matousek</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wagener</surname>
                      <given-names>JS</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis</collab>
                  <article-title>Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis</article-title>
                  <source>
                    <italic>J Pediatr</italic>
                  </source>
                  <year>2003</year>
                  <volume>142</volume>
                  <fpage>624</fpage>
                  <lpage>630</lpage>
                  <pub-id pub-id-type="pmid">12838189</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stallings</surname>
                      <given-names>VA</given-names>
                    </name>
                    <name>
                      <surname>Stark</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Feranchak</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Quinton</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <collab>Clinical Practice Guidelines on Growth and Nutrition Subcommittee</collab>
                  <collab>Ad Hoc Working Group</collab>
                  <article-title>Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review</article-title>
                  <source>
                    <italic>J Am Diet Assoc</italic>
                  </source>
                  <year>2008</year>
                  <volume>108</volume>
                  <fpage>832</fpage>
                  <lpage>839</lpage>
                  <pub-id pub-id-type="pmid">18442507</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wilschanski</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dupuis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ellis</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jarvi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Zielenski</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tullis</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Mutations in the cystic fibrosis transmembrane regulator gene and <italic>in vivo</italic> transepithelial potentials</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2006</year>
                  <volume>174</volume>
                  <fpage>787</fpage>
                  <lpage>794</lpage>
                  <pub-id pub-id-type="pmid">16840743</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>PM</given-names></name><name><surname>White</surname><given-names>TB</given-names></name><name><surname>Ren</surname><given-names>CL</given-names></name><name><surname>Hempstead</surname><given-names>SE</given-names></name><name><surname>Accurso</surname><given-names>F</given-names></name><name><surname>Derichs</surname><given-names>N</given-names></name><etal><italic>et al.</italic></etal></person-group><article-title>Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation</article-title><source><italic>J Pediatr</italic></source><year>2017</year><volume>181S</volume><fpage>S4</fpage><lpage>S15, e1</lpage>. [Published erratum appears in <italic>J Pediatr</italic> 184:243.]<pub-id pub-id-type="pmid">28129811</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McKone</surname>
                      <given-names>EF</given-names>
                    </name>
                    <name>
                      <surname>Velentgas</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Swenson</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Goss</surname>
                      <given-names>CH.</given-names>
                    </name>
                  </person-group>
                  <article-title>Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype</article-title>
                  <source>
                    <italic>J Cyst Fibros</italic>
                  </source>
                  <year>2015</year>
                  <volume>14</volume>
                  <fpage>580</fpage>
                  <lpage>586</lpage>
                  <pub-id pub-id-type="pmid">25660278</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Sermet-Gaudelus</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Naehrlich</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ahluwalia</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <collab>VX16-661-115 Investigator Group</collab>
                  <article-title>A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation</article-title>
                  <source>
                    <italic>J Cyst Fibros</italic>
                  </source>
                  <year>2021</year>
                  <volume>20</volume>
                  <fpage>68</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="pmid">32967799</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McGarry</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>McColley</surname>
                      <given-names>SA.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype</article-title>
                  <source>
                    <italic>Pediatr Pulmonol</italic>
                  </source>
                  <year>2021</year>
                  <volume>56</volume>
                  <fpage>1496</fpage>
                  <lpage>1503</lpage>
                  <pub-id pub-id-type="pmid">33470563</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
